Abstract
The mortality from lung cancer exceeds that from breast, colorectal and pancreatic cancer combined. This is because three-quarters of patients present with late-stage disease when treatment is palliative and survival is short. If detected early, lung cancer can be cured, so screening would seem to be an important intervention. Until the publication of the National Lung Screening Trial (NLST),1 there was no evidence to support the implementation of screening with low-dose CT (LDCT). This publication has sparked a different approach to the subject from asking whether it works to what we still need to know to implement with the least harm and cost. These remaining issues will be reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
